🔗 Share this article The Global Health Body Raises Warning Over Critical Scarcity of Weight-Loss Medications Fewer than 10% of people that would benefit from GLP-1 drugs including Wegovy have access to them, caution the global health agency as it releases its initial recommendations on the drugs. Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to this class of drugs. Based on projections, more than two billion are projected to be obese by 2030 unless action is taken. "Our new guidelines acknowledges that obesity is a long-term condition that can be treated with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the jabs that can assist patients in reducing substantial weight, notes the agency. Skinny Jab Shortage Even under the current best projected scenario, the production of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The advice encourages countries and companies to widen availability, through measures including patent sharing. A patent on the active ingredient – the main component of a leading brand – is scheduled to end in multiple countries in 2026. The Way Weight-Loss Drugs Operate The injections replicate a body's own hormone to delay gastric emptying, suppress the appetite and enhance satiety so users reduce food intake. Patients typically see weight reduction within a few weeks of beginning the once-weekly jabs. Research suggests users may see weight return a year later of halting the treatment, when their normal hunger come back. Being above a healthy weight increases your chance for experiencing diseases, like diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.
Fewer than 10% of people that would benefit from GLP-1 drugs including Wegovy have access to them, caution the global health agency as it releases its initial recommendations on the drugs. Considering in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just access to this class of drugs. Based on projections, more than two billion are projected to be obese by 2030 unless action is taken. "Our new guidelines acknowledges that obesity is a long-term condition that can be treated with thorough and ongoing treatment," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, insufficient output, and logistical bottlenecks are key barriers to widespread availability to the jabs that can assist patients in reducing substantial weight, notes the agency. Skinny Jab Shortage Even under the current best projected scenario, the production of GLP-1 therapies would only suffice for around 100 million people – fewer than 10% of eligible patients, as stated by the WHO. The advice encourages countries and companies to widen availability, through measures including patent sharing. A patent on the active ingredient – the main component of a leading brand – is scheduled to end in multiple countries in 2026. The Way Weight-Loss Drugs Operate The injections replicate a body's own hormone to delay gastric emptying, suppress the appetite and enhance satiety so users reduce food intake. Patients typically see weight reduction within a few weeks of beginning the once-weekly jabs. Research suggests users may see weight return a year later of halting the treatment, when their normal hunger come back. Being above a healthy weight increases your chance for experiencing diseases, like diabetes, cardiovascular issues, stroke, and certain cancers. Excess weight affects people in countries worldwide and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.